Latest news, reports, and more from the RedChip Nation.
Discovering Tomorrow's Blue Chips Today
December 31, 2019     Contact    
Can-Fite BioPharma (NYSE American: CANF) Appoints Univo Pharmaceuticals’ CEO to Board


Can-Fite BioPharma (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and inflammatory diseases, announced that Golan Bitton, CEO of Univo Pharmaceuticals (TASE:UNVO), was elected as a board member to Can-Fite.


Why It Matters: In September 2019, Can-Fite BioPharma and Univo Pharmaceutical, a medical cannabis company, entered into a collaboration agreement to co-develop cannabis derived pharmaceutical products based on the platform technology of Can-Fite in the fields of cancer, inflammatory, autoimmune, and metabolic diseases. Bitton has many years of managerial experience in the Israeli Ministry of Defense. During his tenure there, he Implemented and managed multi-million-dollar projects for the Israeli Government. Golan holds a B.A. in Economics and Business Management from Max Stern Academic College and Computer Engineering from Negev University. Golan is the founder of Univo Pharmaceuticals and is considered today as one of the leading worldwide experts in the cannabis arena.


Key Quote: “We welcome Golan as a board member and trust that his skills will be highly valuable to Can-Fite and also strengthen the collaboration in the cannabis arena, which is intended to lead to new intellectual property and novel pharmaceutical products." – Dr. Pnina Fishman, CEO


The Backstory: Can-Fite is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.



Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly, beginning in August 2019, and 16,500 shares of CANF Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.

Cyclo Therapeutics (OTCQB: CTDH) Signs Master Service Agreement with Worldwide Clinical Trials


CTDH currently supports a Phase I clinical trial for NPC in the U.S., which recently completed enrollment ( NCT02939547); an Extension Protocol for the US study, which includes home-based infusions (NCT03893071); and a Phase I/II trial in Europe and Israel for NPC which is nearing completion of enrollment (NCT02912793). The Company will share its design of a pivotal trial in scientific advice meetings with regulators in the US and Europe in first and second quarters of 2020, respectively.


Key Quote: “We are very excited to take this next step in working with Worldwide, an industry leader in the rare disease and neurological disease space. Worldwide will play a vital role as we build and execute our clinical programs in NPC and Alzheimer’s Disease.” – N. Scott Fine, Chairman & CEO


The Backstory: CTDH currently supports a Phase I clinical trial for NPC in the U.S., which recently completed enrollment ( NCT02939547); an Extension Protocol for the US study, which includes home-based infusions (NCT03893071); and a Phase I/II trial in Europe and Israel for NPC which is nearing completion of enrollment (NCT02912793). The Company will share its design of a pivotal trial in scientific advice meetings with regulators in the US and Europe in first and second quarters of 2020, respectively.



Cyclo Therapeutics (CTDH) is a client of RedChip Companies, Inc. CTDH paid RedChip Companies, Inc. a fee of $30,000 per month for four months, beginning in August 2019, and a monthly fee of $7,500, beginning December 2019, for RedChip investor awareness services and consulting services. RedChip's CEO owns 146,128 shares of CTDH stock.

Digital Ally (NASDAQ: DGLY) Receives New Patent for Law Enforcement Technology


Digital Ally (NASDAQ: DGLY), which develops, manufactures and markets advanced video recording products for law enforcement, emergency management, fleet safety and security, announced the pending addition of U.S. Patent No. 10,521,675 (the “675 Patent”) to the Company’s patent portfolio.


Why It Matters: The ‘675 Patent is the first of its kind for the Company, allowing the software from the recording video cameras to scan film frame by frame to capture and store legible vehicle markings, such as license plate characters. The ‘675 Patent will be useful for law enforcement officers when conducting traffic stops and especially at nightfall when objects may be obscured by challenging lighting conditions and interfere with the camera’s ability to capture legible markings or characters. When a recording is activated by various triggers (i.e., vehicle sirens or signal lights) the recording camera system will initiate two base scans, considering ambient light levels, light gains, shutter speed and white balance. If vehicle markings are legibly captured, the system will automatically store and upload the frame in the Company’s back-office solution for the law enforcement agency’s use.


Key Quote: “The issuance of Patent ‘675 is very exciting for us. This is our first patent that utilizes computer recognition software. Our entire team at Digital Ally has worked hard and the ‘675 Patent marks the conclusion of a very successful year of innovation. We are excited for our prospects for the immediate and long-term future.” – Stan Ross, CEO


The Backstory: Headquartered in Lenexa, Kansas, DGLY specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, fleet safety and security. Digital Ally’s complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.



Digital Ally, Inc. (DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a $7,500 monthly cash fee, beginning in September 2017, for RedChip investor awareness services.

Santa Fe Gold (OTC: SFEG) to Begin Recommissioning its Billali Mine


Santa Fe Gold (OTC: SFEG), a U.S. based mining company that currently ranks 9th out of the top ten US based mid-tier and junior precious metals companies (as cited by mining industry trade journal, The Northern Miner) with 148 mining claims covering 42 mine sites and potential mines, plans to begin recommissioning its Billali mine to substantially increase output of its economic grade, high silica vein gold and silver siliceous vein material


Key Quote: “We are very pleased to announce expected further increases in output and shipments from the already producing Jim Crow mine, soon be augmented by new production from what we believe will be higher potential output from the Billali Mine that is expected to continue well into the future in annual output. This should enable Santa Fe to ramp up production substantially over coming quarters and beyond. Thereafter, it is expected Santa Fe will begin preparations to commence production from its Gold King and Imperial Mines, as sustainable output is achieved from Billali and Jim Crow to maintainable levels. We believe production from multiple mines will have significant longer term impact on our bottom line.” – Brian Adair, Chairman


The Backstory: Santa Fe Gold is a US-based mining and exploration enterprise with 148 mining claims comprising 42 potential mines of which Jim Crow Gold and Silver Mine is already in production. Jim Crow is the first of 11 potential mines in the mining rich Steeple Rock Billali district, with additional mines expected to be brought into production soon. Santa Fe’s goal is to produce near term cash flows from its numerous mine sites, while creating a portfolio of high-quality exploration and bankable development projects, to ensure future revenue growth.



Santa Fe Gold Corp. (SFEG) is a client of RedChip Companies, Inc. SFEG agreed to pay RedChip Companies, Inc. 1,000,000 shares of Rule 144 stock for 12 months of RedChip investor awareness services and consulting services.

Quote of the Week
"Higher returns, of course, come with more risk...the trade off is, yes, you get long-term outperformance ... but the volatility of returns is greater... That's the price you pay if you want exposure to a better-performing asset class."
- Samuel Dedio, Manager of the Artio U.S. Microcap Fund (JMCAX)
Lesson of the Week
Mitigate Risk by Buying Small-Caps in Bunches
Read More
Latest Videos
Dividend Paying REIT with $4.75 Price Target from Aegis
Medalist Diversified REIT (NASDAQ: MDRR) is a public Virginia-based Real Estate Investment Trust specializing in acquiring, owning and managing value-add commercial real estate in the Southeast. The Company’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns. Medalist utilizes a rigorous, consistent and replicable process for sourcing and conducting due diligence of acquisitions. The Company seeks to maximize operating performance of current properties by utilizing a hands-on approach to property management while monitoring the middle market real estate markets in the Southeast for acquisition opportunities and disposal of properties as considered appropriate.
Watch Now
Boxlight CEO Interview: Double-Digit Growth for Leading Interactive Tech Provider
Boxlight (Nasdaq: BOXL) is a leading provider of technology solutions for the global education market. The company aims to improve learning and engagement in classrooms and to help educators enhance student outcomes, by developing the products they need. The company develops, sells, and services its integrated, interactive solution suite including software, classroom technologies, professional development and support services.
Watch Now
Can-Fite CEO Interview: Multiple Phase III Clinical Trial Programs
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH.
Watch Now
Immuron's New Antibiotic Alternative Generating Strong Sales Growth
Immuron Ltd. (NASDAQ: IMRN; ASX: IMC), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
Watch Now
Interview with Leading Tech Developer for Maritime Industry
eMARINE Global (OTC: EMRN) is a leading provider of information and communications technology (ICT) solutions for the global maritime industry.
Watch Now
Preferred Shares Pay Quarterly Distributions at 12% Per Annum Rate
1847 Holdings (OTC: EFSH) seeks to provide non-correlated returns by combining the most attractive attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly-traded company. 1847’s unique structure permits flow-through tax treatment for shareholders. As a result, 1847 will seek to generate returns for shareholders through consistent, annual distributions of operating subsidiary income and capital appreciation resulting from the timely sale of operating subsidiaries.
Watch Now
Can-Fite BioPharma Webinar
Watch our exclusive investor webinar with Can-Fite BioPharma Ltd. (NYSE American: CANF) CEO Dr. Pnina Fishman to learn why the stock has been attracting positive attention this year and what the upside potential is from here.
Watch Now
SinglePoint: Diversified Operations Driving Rapid Revenue Growth
SinglePoint (OTCQB: SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. The company portfolio includes mobile payments, ancillary cannabis services, solar, and blockchain solutions.
Watch Now
Genetic Technologies: New Risk Assessment Tests for Cancer
Exclusive interview with Dr. Jerzy Mechnicki , interim-CEO of Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.
Watch Now
BioTech Stock Cyclo Therapeutics Begins World Wide Trial for Alzheimer's Medication
Cyclo Therapeutics (OTCQB: CTDH) is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C (NPC), a rare and fatal genetic disease, on a compassionate use basis as well as in three ongoing formal clinical trials.
Watch Now
Order Small Stocks, Big Money Today!
Dave Gentry is the author of Small Stocks, Big Money: Interviews With Microcap Superstars. Published by Wiley, this first-hand perspective on the fast world of microcap investing is now available for purchase.
MidSouth Week in Review
3Q corporate profits suffered their third straight quarterly contraction. Analysts expect another decline in the 4Q before profits start to accelerate again in 2020.
Read More
Weekly Index Performance
NASDAQ topped 9,000 last week as major indexes notched minor gains.
Read More
About RedChip
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at and view RedChip’s Disclosures.
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.